Sage Journals: Discover world-class research

Abstract

OBJECTIVE: To explore the relationships between serum concentrations of tissue inhibitor of metalloproteinase-2 (TIMP-2) and matrix metalloproteinase-2 (MMP-2), and severity of liver fibrosis in chronic hepatitis B. METHODS: A total of 101 patients with hepatitis B and 54 healthy control subjects were consecutively enrolled. Serum MMP-2 and TIMP-2 were quantified by enzyme-linked immunosorbent assay. RESULTS: Serum MMP-2 concentrations in patients with stage F2 – F4 fibrosis were significantly higher than in patients with stage F0 – F1 fibrosis and control subjects, but no significant difference was found between patients with stage F0 – F1 fibrosis and control subjects. Significant differences in serum TIMP-2 concentrations were found between patients with stages F2 – F4 and F0 – F1 fibrosis, and between stages F0 – F1 fibrosis and healthy control subjects. Areas under the receiver operating characteristic curves of serum TIMP-2 and MMP-2 for predicting clinically significant fibrosis (stage F2 – F4) were 0.899 and 0.770, respectively. CONCLUSION: Serum TIMP-2 and MMP-2 assessment may represent a valuable noninvasive diagnostic test for liver fibrosis in hepatitis B.

Keywords

Hepatitis B Liver Fibrosis Matrix Metalloproteinase-2 (MMP-2)Tissue Inhibitor of Metalloproteinase-2 (TIMP>-2)

References

Afdhal

Nunes

: Evaluation of liver fibrosis: A concise review. Am J Gastroenterol 2004; 99: 1160–1174.

Fierbinteanu-Braticevici

Purcarea

: Non-biopsy methods to determine hepatic fibrosis. J Med Life 2009; 2: 401–406.

Little

Ferris

Dodd

3rd : Image-guided percutaneous hepatic biopsy: effect of ascites on the complication rate. Radiology 1996; 199: 79–83.

Lindor

Bru

Jorgensen

: The role of ultrasonography and automatic-needle biopsy in outpatient percutaneous liver biopsy. Hepatology 1996; 23: 1079–1083.

Bataller

Sancho-Bru

Ginès

: Liver fibrogenesis: A new role for the reninangiotensin system. Antioxid Redox Signal 2005; 7: 1346–1355.

Regev

Berho

Jeffers

: Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97: 2614–2618.

Bedossa

Dargère

Paradis

: Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38: 1449–1457.

Pinzani

Rombouts

Colagrande

: Fibrosis in chronic liver diseases: diagnosis and management. J Hepatol 2005; 42 (suppl): S22–S36.

Friedman

: Liver fibrosis—from bench to bedside. J Hepatol 2003; 38 (suppl 1): S38–S53.

10.

Nelson

Fingleton

Rothenberg

: Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000; 18: 1135–1149.

11.

Nagase

Woessner

Jr : Matrix metalloproteinases. J Biol Chem 1999; 274: 21491–21494.

12.

Watanabe

Nishizaki

Kojima

: Clinical significance of serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in chronic liver disease. Tokai J Exp Clin Med 2006; 31: 96–101.

13.

Theise

: Liver biopsy assessment in chronic viral hepatitis: A personal, practical approach. Mod Pathol 2007; 20 (suppl 1): S3–S14.

14.

Strader

Wright

Thomas

: Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 1147–1171.

15.

Ceriotti

Henny

Queraltó

: Common reference intervals for aspartate aminotransferase (AST), alanine aminotransferase (ALT) and γ-glutamyl transferase (GGT) in serum: results from an IFCC multicenter study. Clin Chem Lab Med 2010; 48: 1593–1601.

16.

Boeker

Haberkorn

Michels

: Diagnostic potential of circulating TIMP-1 and MMP-2 as markers of liver fibrosis in patients with chronic hepatitis C. Clin Chim Acta 2002; 316: 71–81.

17.

Benyon

Iredale

Goddard

: Expression of tissue inhibitor of metalloproteinases 1 and 2 is increased in fibrotic human liver. Gastroenterology 1996; 110: 821–831.

18.

Milani

Herbst

Schuppan

: Differential expression of matrix-metalloproteinase-1 and–2 genes in normal and fibrotic human liver. Am J Pathol 1994; 144: 528–537.

19.

Benyon

Hovell

Da Gaça

: Progelatinase A is produced and activated by rat hepatic stellate cells and promotes their proliferation. Hepatology 1999; 30: 977–986.

20.

Ebata

Fukuda

Nakano

: Serum levels of tissue inhibitor of metalloproteinases-2 and of precursor form of matrix metalloproteinase-2 in patients with liver disease. Liver 1997; 17: 293–299.

21.

Walsh

Timms

Campbell

: Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases-1 and–2 (TIMP-1 and TIMP-2) as noninvasive markers of liver disease in chronic hepatitis C: comparison using ROC analysis. Dig Dis Sci 1999; 44: 624–630.

22.

Kasahara

Hayashi

Mochizuki

: Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C. Relationship to interferon response. J Hepatol 1997; 26: 574–583.

23.

Lebensztejn

Skiba

Sobaniec-Łotowska

: Matrix metalloproteinases and their tissue inhibitors in children with chronic hepatitis B treated with lamivudine. Adv Med Sci 2007; 52: 114–119.

24.

Baranova

Lal

Birerdinc

: Non-invasive markers for hepatic fibrosis. BMC Gastroenterol 2011; 11: 91.

25.

Arthur

: Collagenases and liver fibrosis. J Hepatol 1995; 22: 43–48.

26.

Herbst

Wege

Milani

: Tissue inhibitor of metalloproteinase-1 and–2 RNA expression in rat and human liver fibrosis. Am J Pathol 1997; 150: 1647–1659.

27.

Murawaki

Ikuta

Kawasaki

: Clinical usefulness of serum tissue inhibitor of metalloproteinases (TIMP)-2 assay in patients with chronic liver disease in comparison with serum TIMP-1. Clin Chim Acta 1999; 281: 109–120.

28.

Ueno

Tamaki

Sugawara

: Significance of serum tissue inhibitor of metalloproteinases-1 in various liver diseases. J Hepatol 1996; 24: 177–184.

29.

Muzzillo

Imoto

Fukuda

: Clinical evaluation of serum tissue inhibitor of metalloproteinases-1 levels in patients with liver diseases. J Gastroenterol Hepatol 1993; 8: 437–441.

30.

Afdhal

: Biopsy or biomarkers: is there a gold standard for diagnosis of liver fibrosis? Clin Chem 2004; 50: 1299–1300.

31.

Ichino

Osakabe

Nishikawa

: A new index for non-invasive assessment of liver fibrosis. World J Gastroenterol 2010; 16: 4809–4816.

32.

Tripepi

Jager

Dekker

: Diagnostic methods 2: receiver operating characteristic (ROC) curves. Kidney Int 2009; 76: 252–256.

33.

Hongbo

Xiaohui

Hong

: Assessing routine and serum markers of liver fibrosis in CHB patients using parallel and serial interpretation. Clin Biochem 2007; 40: 562–566.

34.

Rossi

Adams

Bulsara

: Assessing liver fibrosis with serum marker models. Clin Biochem Rev 2007; 28: 3–10.

35.

Heymans

Schroen

Vermeersch

: Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart. Circulation 2005; 112: 1136–1144.

36.

Kitamura

Oosawa

Kawano

: Basement membrane patterns, gelatinase A and tissue inhibitor of metalloproteinase-2 expressions, and stromal fibrosis during the development of peripheral lung adenocarcinoma. Hum Pathol 1999; 30: 331–338.

37.

Kim

Choeng

Ahn

: Early and late changes of MMP-2 and MMP-9 in bleomycin-induced pulmonary fibrosis. Yonsei Med J 2009; 50: 68–77.

Clinical Utility of Serum Matrix Metalloproteinase-2 and Tissue Inhibitor of Metalloproteinase-2 Concentrations in the Assessment of Liver Fibrosis due to Chronic Hepatitis B

Abstract

Keywords

References